Trial Profile
Use of Glycerol Phenylbutyrate (Ravicti) as a Chaperone to Stabilize Enzyme in Patients With MCAD Deficiency Due to the Common MCAD 985A>G (K304E) Mutation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glycerol phenylbutyrate (Primary)
- Indications Medium chain acyl CoA dehydrogenase deficiency
- Focus Therapeutic Use
- 02 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 May 2015 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 26 May 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.